SPOC Proteomics

Our SPOC team will be at Bio-IT World Conference & Expo in Boston next week, Apr 2nd-4th! Manager of Bioassay Development, Dr. Chidozie Agu, PhD, will be ???????????????? ?????? ?????????????? "?????????????????? ???? ?????????????????????? ?????? ???????????????????? ???? ????????????" ???? ?????? ???????????????????? ???? ?????????? on Thurs, Apr 3rd at 2:25 pm. ? Stop by Poster P53 or our Expo Booth?119 to discuss how SPOC can integrate with your AI drug discovery workflows to support high-plex affinity screening of scFv/VHH libraries, including affinity maturation and paratope characterization. ? SPOC delivers high-resolution kinetic binding data at scale, combined with ~60% reduction in cost and time-to-results compared to traditional workflows. ? Check out the session here ?? https://lnkd.in/g5bN89Mk Check out Poster P53 here ?? https://lnkd.in/de9iB-S3 ? #SPOCProteomics #ProteinKineticsAtScale #KineticProteomics #spr #antibodytherapeutics #drugdiscovery #aidrugdiscovery #BioITExpo #BioIT Cambridge Healthtech Institute

We are happy to share the publication of our first SPOC paper in Nature Communications Biology! ?? ? Our team developed a single-step process for protein synthesis, purification, and capture onto SPR biosensor chips, at scale. We showcase SPOC technology's ability to produce 1,000 - 2,400 folded proteins directly on SPR biosensor chips for simultaneous kinetic screening of thousands of protein binding interactions. ? Proteins are synthesized and purified cell-free in as little as 4 hours, directly from DNA constructs, essentially breaking-down the time and cost barriers of traditional recombinant protein production workflows to enable high-throughput kinetic proteomics. ? Read the full paper here ?? https://lnkd.in/giYqvc8W #SPOCProteomics #ProteinKineticsAtScale #KineticProteomics #SPR #highthroughput

Great work from?Prescient Design,?Genentech, and Roche?on using deep learning with a 'Lab-in-the-Loop' system for antibody drug design. This paper showcases the power of combining AI/ML with wet lab testing of 1800 antibody candidates, achieving 3-100x improved binding for 4 targets through 4 rounds of selection. Their unique workflow enabled optimization of multiple parameters simultaneously, with kinetic SPR data a key feature used for informing affinity maturation of animal-derived sequences in their iterative ML-powered Lab-in-the-Loop workflow. At SPOC Proteomics, we designed our SPOC platform to support such high-plex SPR affinity screening needs required to train and validate AI-enabled therapeutic antibody development workflows, such as the showcased Lab-in-the-Loop approach. SPOC enables simultaneous synthesis and affinity screening of up to 1000 antibody sequence candidates to support affinity ranking, epitope mapping, and affinity maturation, whilst cutting-out the expensive and time consuming cell-based antibody production and purification methods - to deliver data at reduced cost and time. Our approach is detailed in our recent preprint:?https://lnkd.in/g2U6gBm6 Very interesting work Nathan Frey, Richard Bonneau, Vladimir Gligorijevi?!

If you are interested in scFv/VHH antibody libraries synthesized directly on SPOC SPR chips at reduced costs, for pico-molar resolution protein/drug binding kinetics, come see us at SLAS (Society for Laboratory Automation and Screening) 2025 in San Diego this week, Jan 27-29th! ? ?? Manager of Bioassay Development, Dr. Chidozie Agu, PhD, will present an overview of SPOC technology and how it supports antibody drug discovery in the Solutions Spotlight Theater at noon on Wed, Jan 29th. ?? Visit our team at our expo hall booth 147 all week. ?? Dr. Agu will also be presenting a poster during Poster Session D, from 2-3 pm on Jan 28th, showcasing our new exciting data on producing and screening scFv/VHH libraries directly on SPOC biosensors featured in our latest pre-print. ? Check it out here ?? https://lnkd.in/g4BrJKFj ? #SPOCProteomics #ProteinKineticsAtScale #KineticProteomics #SLAS2025 #spr #antibodytherapeutics #drugdiscovery #aidrugdiscovery?

AI-driven discovery still struggles with low hit rates—validation has yet to catch up with prediction. To stay ahead without breaking the bank, we need scalable validation and testing methods that can keep pace with AI’s speed. The antibody space offers a few promising technologies, but we need more across the board.

Really cool technology that allows for screening binding kinetics of thousands of binders in a single run. This approach can provide deep insight into antibody paratope and residue-level CDR contributions to binding. I believe what SPOC Proteomics is building will be the future of binder kinetic characterization. I really enjoyed the thoughtful discussions around this technology with Bharath Takulapalli and Lydia Gushgari. I appreciate the shoutout in the acknowledgments section ??

An approach to produce thousands of single-chain antibody variants on a SPR biosensor chip for measuring target binding kinetics and for deep characterization of antibody paratopes ABSTRACT Drug discovery continues to face a staggering 90% failure rate, with many setbacks occurring during late-stage clinical trials. To address this challenge, there is an increasing focus on developing and evaluating new technologies to enhance the "design" and "test" phases of antibody-based drugs (e.g., monoclonal antibodies, bispecifics, CAR-T therapies, ADCs) and biologics during early preclinical development, with the goal of identifying lead molecules with a higher likelihood of clinical success. Artificial intelligence (AI) is becoming an indispensable tool in this domain, both for improving molecules identified through traditional approaches and for the de novo design of novel therapeutics. However, critical bottlenecks persist in the "build" and "test" phases of AI-designed antibodies and protein binders, impeding early preclinical evaluation. While AI models can rapidly generate thousands to millions of putative drug designs, technological and cost limitations mean that only a few dozen candidates are typically produced and tested. Drug developers often face a tradeoff between ultra-high-throughput wet lab methods that provide binary yes/no binding data and biophysical methods that offer detailed characterization of a limited number of drug-target pairs. To address these bottlenecks, we previously reported the development of the Sensor-integrated Proteome On Chip (SPOC?) platform, which enables the production and capture-purification of 1,000-2,400 folded proteins directly onto a surface plasmon resonance (SPR) biosensor chip for measuring kinetic binding rates with picomolar affinity resolution. In this study, we extend the SPOC technology to the expression of single-chain antibodies (sc-antibodies), specifically scFv and VHH constructs. We demonstrate that these constructs are capture-purified at high levels on SPR biosensors and retain functionality as shown by the binding specificity to their respective target antigens, with affinities comparable to those reported in the literature. SPOC outputs comprehensive kinetic data including quantitative binding (Rmax), on-rate (ka), off-rate (kd), affinity (KD), and half-life (t1/2), for each of thousands of on-chip sc-antibodies. Additionally, we present a case study showcasing single amino acid mutational scan of the complementarity-determining regions (CDRs) of a HER2 VHH (nanobody) paratope. Using 92 unique mutated variants from four different amino acid substitutions, we pinpoint critical residues within the paratope that could further enhance binding affinity. This study serves as a demonstration of a novel high-throughput approach for biophysical screening of hundreds to thousands of single chain antibody sequences in a single assay… PAPER: https://lnkd.in/dAK_7Nfi

If you're at PepTalk and interested in antibody fragment libraries on SPR chips, stop by booth 208 to chat with our team and visit our poster at B44! #SPOCProteomics #ProteinKineticsAtScale #KineticProteomics #CHIPepTalk #antibodytherapeutics #drugdiscovery #aidrugdiscovery Cambridge Healthtech Institute

We are excited to announce the release of our second pre-print publication now available on bioRxiv: "An approach to produce thousands of single-chain antibody variants on a SPR biosensor chip for measuring target binding kinetics and for deep characterization of antibody paratopes"! ? Our team developed the capability to produce antibody-fragment libraries of scFvs and VHHs (nanobodies) directly on SPOC SPR biosensor chips, facilitating high affinity resolution screening to generate kinetic data from 100s to 1000s of on-chip VHHs/scFvs at once. We demo producing and screening 92 VHH CDR mutational sequences to characterize the paratope, to support antibody drug design, including affinity maturation campaigns and AI-enabled workflows. Check it out here ?? https://lnkd.in/gVzaQAJJ ? If you missed Lydia's talk at the ongoing PepTalk & Biologics Summit, catch us at booth 208 or poster B44 the rest of the week. Or meet us at SLAS Jan 27 – 29th in San Diego. ? Meet us at PepTalk Jan 14-16th: ?? Expo Hall Booth 208 ?? Jan 15-16th, Poster B44 during Poster Session B ? Meet us at SLAS Jan 27-29th: ?? Solutions Spotlight - SPOC Proteomics: Wednesday, Jan 29th 12:00 – 12:20 PM ?? Expo Hall Booth 147 ?? Poster presentation ? #SPOCProteomics #ProteinKineticsAtScale #KineticProteomics #CHIPeptalk #SLAS2025 #spr #kinetics #drugdiscovery #antibodytherapeutics #aidrugdiscovery

We wanted to say thank you to all those who made our presentation at the Cambridge Healthtech Institute PepTalk Predictive Protein Production symposia a success yesterday! Thanks to Dr. Lydia Gushgari and Dr. Chidozie Agu, PhD for representing the SPOC team and to our collaborator and co-presenter Astrid Musnier from MAbSilico for a great talk and discussion. We would also like to thank our chairperson Matthew Coleman and track organizers MaryAnn Brown and Lynn Brainard for running such a great session! We are looking forward to the rest of the week. ? Catch us at booth 208 or poster B44 if you missed our presentation! The expo hall opens at 10:40 AM! ? #SPOCProteomics #ProteinKineticsAtScale #KineticProteomics #CHIPepTalk #spr #antibodytherapeutics #drugdiscovery #aidrugdiscovery